Test Price
2,800 AED✅ Home Collection Available
PDCD10 Gene Cerebral Cavernous Malformations Type 3 Genetic Test in UAE | 2800 AED | DHA-Licensed
Executive Summary & Core Metrics
UAE Clinical Trust Promise
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The PDCD10 gene NGS test sequences the entire coding region to detect pathogenic variants causing Cerebral Cavernous Malformations Type 3 (CCM3), an inherited vascular disorder associated with cerebral and spinal cavernous angiomas. This test provides essential risk information for family screening, surgical planning, and monitoring of disease progression. Comprehensive sequencing achieves deep coverage of all exons and splice sites, enabling reliable detection of single-nucleotide variants, small insertions, and deletions. For larger structural rearrangements, MLPA analysis is performed as a complementary method to ensure full diagnostic yield.
| Feature | Our PDCD10 NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full-gene Next Generation Sequencing (coding ≥99.5% coverage at >20x) | Single-site mutation panels / limited hotspot analysis |
| Methodology | Illumina NovaSeq with MLPA backup for large deletions | Sanger sequencing (gene-by-gene, slower, no CNV detection) |
| Speed | 3–4 Weeks with secure digital report | 6–10 Weeks standard, often without clinical interpretation |
| Clinical Integration | Pre-test genetic counselling & post-test tele-consultation inclusive | Counselling often outsourced or unavailable |
Physician Insight & Safety Protocols
“A pathogenic PDCD10 variant confirms CCM3 with high penetrance, but genotype-phenotype correlation remains essential. I emphasize that negative sequencing does not fully exclude mosaicism or deep intronic variants, and MRI surveillance protocols should continue when clinical suspicion is elevated. Cascade screening of first-degree relatives is strongly recommended for all probands with a confirmed mutation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Important Advisory
Clinical Safety Advisory for Patients
Do not discontinue or alter any prescribed medication (including antiepileptics, antihypertensives, or anticoagulants) based solely on genetic test results. Any changes to your treatment plan must be discussed directly with your managing physician. Genetic findings inform surveillance and family screening but do not replace acute medical management.
- Emergency Red Flag: Sudden severe headache, new-onset seizure, focal neurological deficit, or loss of consciousness — proceed immediately to the nearest emergency department and inform staff of known CCM diagnosis.
- Informed Consent: Written consent is mandatory before sample collection, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. For minors, guardian consent is required.
Patient Exclusion Criteria
Conditions That May Affect Test Validity
- Recent blood transfusion (< 2 weeks) or bone marrow transplant — DNA from buccal swab or FTA card may be preferred to avoid donor DNA contamination.
- Inability to provide informed consent — written consent is required per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Active haematological malignancy may interfere with germline DNA analysis; discuss alternatives with the referring clinician.
Patient FAQ & Clinical Guidance
1. What is the PDCD10 genetic test, and why do I need it?
Answer: This DNA test sequences the PDCD10 gene to identify mutations causing familial cerebral cavernous malformations type 3, enabling accurate risk assessment, family screening, and proactive neuroimaging follow-up. The test is indicated for individuals with a personal or family history of CCM lesions, especially when multiple cavernomas are present or a CCM3 subtype is suspected.
2. Can a home blood collection be used for this genetic test?
Answer: Yes, our DHA-licensed VIP mobile phlebotomy service collects a small blood sample or buccal swab (FTA card) at your home, office, or hotel with full cold-chain compliance. Service is available daily from 8 AM to 11 PM. The sample remains stable for analysis when handled according to our standard operating procedures.
3. How is my genetic data protected under UAE law?
Answer: Your genomic data is stored on encrypted servers in Dubai under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Access is limited to the ordering physician and yourself; no third-party sharing occurs without your explicit written consent.
4. What does a negative result mean for me and my family?
Answer: A negative result reduces the likelihood of a germline PDCD10 mutation but does not eliminate the possibility of mosaicism, deep intronic variants, or a different CCM gene (CCM1/KRIT1 or CCM2/MGC4607). If clinical suspicion remains high, MRI surveillance and genetic counselling are still recommended. Cascade screening is advised only when a pathogenic variant has been identified in the proband.
UAE Regulatory & Data Privacy Adherence
Compliance with UAE Health Data Protection Frameworks
- Data Privacy: All genetic data is processed and stored under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Results are shared only with the referring physician unless the patient provides explicit written consent for additional disclosure.
- Health ICT Law: Our digital health systems comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure transmission and storage of electronic medical records.
- Medical Liability: Patient consent and clinical safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all procedures are performed with the highest standard of care.
Clinical & Logistical Metadata
| Test Name | PDCD10 Gene Cerebral Cavernous Malformations Type 3 Genetic Test (NGS + MLPA) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Buccal Swab, or FTA Card |
| Methodology Used | Next Generation Sequencing (Illumina NovaSeq) with MLPA confirmation for large deletions/duplications |
| ICD-10-CM Code | Q28.3, I67.1 |
| LOINC Code | 21665-0 |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians